The following tables set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the Company’s unaudited condensed consolidated statements of operations as follows (in thousands):


	For the Three Months Ended September 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	2,966,966	$	—	$	2,966,966
Services revenue		—		367,140		367,140
Cost of drugs		2,541,723		—		2,541,723
Cost of services		—		220,784		220,784
Other direct costs (1)		179,591		—		179,591
Segment selling, general, and administrative expenses (2)		131,116		93,027		224,143
Segment depreciation and amortization expense (3)		26,451		7,340		33,791
Segment EBITDA	$	140,987	$	60,669	$	201,656


	For the Three Months Ended September 30, 2024
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	2,265,697	$	—	$	2,265,697
Services revenue		—		335,532		335,532
Cost of drugs		1,920,089		—		1,920,089
Cost of services		—		201,016		201,016
Other direct costs (1)		157,032		—		157,032
Segment selling, general, and administrative expenses (2)		117,336		88,507		205,843
Segment depreciation and amortization expense (3)		27,913		6,270		34,183
Segment EBITDA	$	99,153	$	52,279	$	151,432


	For the Nine Months Ended September 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	8,289,238	$	—	$	8,289,238
Services revenue		—		1,070,695		1,070,695
Cost of drugs		7,066,776		—		7,066,776
Cost of services		—		648,773		648,773
Other direct costs (1)		539,155		—		539,155
Segment selling, general, and administrative expenses (2)		382,894		275,000		657,894
Segment depreciation and amortization expense (3)		80,992		21,283		102,275
Segment EBITDA	$	381,405	$	168,205	$	549,610


	For the Nine Months Ended September 30, 2024
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	6,357,223	$	—	$	6,357,223
Services revenue		—		968,026		968,026
Cost of drugs		5,356,206		—		5,356,206
Cost of services		—		581,509		581,509
Other direct costs (1)		459,775		—		459,775
Segment selling, general, and administrative expenses (2)		341,803		254,779		596,582
Segment depreciation and amortization expense (3)		82,384		17,963		100,347
Segment EBITDA	$	281,823	$	149,701	$	431,524

(1)

Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets.

(2)

Segment selling, general, and administrative expense includes direct labor costs, depreciation and amortization, insurance, rent, lease, supplies, professional services, maintenance, repairs, utilities, and communications expense.

(3)

Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.


	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2025		2024			2025		2024
Reconciliation of income or loss:
Total Segment EBITDA	$	201,656	$	151,432		$	549,610	$	431,524
Segment depreciation and amortization		33,791		34,183			102,275		100,347
Expenses not allocated at segment level:
Selling, general, and administrative expenses		73,060		81,802			239,047		259,640
Depreciation and amortization		6,962		6,350			21,149		19,122
Loss on extinguishment of debt		—		—			—		12,726
Interest expense, net		38,235		46,614			118,776		144,366
Income tax expense (benefit)		12,120		8,155			13,118		(31,464	)
Net income (loss) from continuing operations	$	37,488	$	(25,672	)	$	55,245	$	(73,213	)